Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer
Metrics: PDF 1513 views | HTML 1920 views | ?
Stefan Kiechl1, Daniel Schramek2,3, Martin Widschwendter4, Evangelia-Ourania Fourkala4, Alexey Zaikin4,5, Allison Jones5, Bernadette Jaeger4, Brigitte Rack4, Wolfgang Janni6, Christoph Scholz7, Johann Willeit1, Siegfried Weger8, Agnes Mayr8, Andrew Teschendorff9, Adam Rosenthal10, Lindsay Fraser5, Susan Philpott5, Louis Dubeau11, Mohammed Keshtgar12, Rebecca Roylance10, Ian J. Jacobs4,13, Usha Menon4, Georg Schett14 and Josef M. Penninger2
1 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
2 IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
3 The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
4 Department of Women’s Cancer, EGA Institute of Women’s Health, University College London, London, United Kingdom
5 Department of Mathematics, University College London, London, United Kingdom
6 Department of Gynecology and Obstetrics, University Duesseldorf, Duesseldorf, Germany
7 Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany
8 Department of Internal Medicine, Bruneck Hospital, Bruneck, Italy
9 Statistical Genomics Group, Paul O’Gorman Building, UCL Cancer Institute, University College London, London, United Kingdom
10 Barts Cancer Institute CR UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London, United Kingdom
11 Department of Pathology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
12 Department of Surgery, Royal Free and University College London Medical School, London, United Kingdom
13 UNSW Australia, Sydney, New South Wales, Australia
14 Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Josef M. Penninger, email:
Keywords: breast cancer, RANKL/RANK, Gerotarget
Received: October 10, 2016 Accepted: December 05, 2016 Published: December 18, 2016
Breast cancer is the most common female cancer, affecting approximately one in eight women during their lifetime in North America and Europe. Receptor Activator of NF-kB Ligand (RANKL), its receptor RANK and the natural antagonist osteoprotegerin (OPG) are essential regulators of bone resorption. We have initially shown that RANKL/RANK are essential for hormone-driven mammary epithelial proliferation in pregnancy and RANKL/RANK have been implicated in mammary stem cell biology. Using genetic mouse-models, we and others identified the RANKL/RANK system as a key regulator of sex hormone, BRCA1-mutation, and oncogene-driven breast cancer and we proposed that RANKL/RANK might be involved in the initiation of breast tumors. We now report that in postmenopausal women without known genetic predisposition, high RANKL and progesterone serum levels stratify a subpopulation of women at high risk of developing breast cancer 12-24 months before diagnosis (5.33-fold risk, 95%CI 1.5-25.4; P=0.02). In women with established breast cancer, we demonstrate that RANKL/OPG ratios change dependent on the presence of circulating tumor cells (CTCs). Finally, we show in a prospective human breast cancer cohort that alterations in RANKL/OPG ratios are significantly associated with breast cancer manifestation. These data indicate that the RANKL/RANK/OPG system is deregulated in post-menopausal women at high risk for breast cancer and in women with circulating tumor cells. Thus, serum levels of RANKL/OPG are potentially indicative of predisposition and progression of breast cancer in humans. Advancement of our findings towards clinical application awaits prior validation in independent patient cohorts.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.